AI agents will streamline clinical trials and reduce administrative burdens, while AI models will enhance drug discovery and digital pathology.

Mayo Clinic's Digital Pathology platform has amassed a database of 10 million patient records and 20 million high-resolution slide images, which are crucial for developing AI models.

The collaboration aims to create more capable AI agents, which are digital robots designed for autonomous decision-making and task execution.

By automating complex tasks such as document generation and patient recruitment, these AI agents will allow healthcare professionals to concentrate on strategic decision-making.

The collaboration will also focus on creating human digital twins to simulate and optimize patient health outcomes for clinical trials and surgical planning.

The partnership aims to enhance IQVIA Healthcare-grade AI™, automating complex workflows throughout the therapeutic life cycle.

Kimberly Powell, NVIDIA's VP of healthcare, emphasized the potential of AI to improve disease detection and treatment discovery, addressing challenges in the $10 trillion healthcare industry.

IQVIA operates in over 100 countries, boasting the largest healthcare network with extensive information, analytics, and technologies.

This initiative is expected to improve efficiencies, facilitate new operating models, and enhance patient outcomes across the healthcare sector.

IQVIA has entered into a strategic collaboration with NVIDIA, aiming to leverage artificial intelligence in the healthcare and life sciences sectors.

The partnership is set to accelerate advancements in clinical research, genomics AI development, and drug discovery.

Initial AI solutions from this collaboration are expected to launch within the 2025 calendar year.